BRAF and non-small cell lung carcinoma: Current treatment guidelines still prioritize BRAF TKI therapy for BRAF V600E-mutant NSCLC, guided by clinical trial data that indicated better survival outcomes (median PFS of 14.6 months with first-line BRAF TKIs; median PFS of 5–8.6 months with BRAF TKIs in subsequent lines of therapy) (4, 21).